Allergic Conjunctivitis Market: By Drug Class (Antihistamines  Mast Cell Stabilizers, Corticosteroids, others), By Disease Type (mild and Severe), By Distribution Channel (Hospital pharmacies, drug Stores, Retail Pharmacies, and Online Pharmacies), and By Geography  

Allergic Conjunctivitis Market size was valued at USD 2,443.9 million in 2023 and is anticipated to grow at a CAGR of 6.1% from 2024-2030. Allergic Conjunctivitis Market refers to the pharmaceutical and healthcare industry's segment that deals with the diagnosis, treatment, and management of allergic conjunctivitis. Allergic conjunctivitis is a common eye condition caused by allergies, resulting in inflammation of the conjunctiva (the thin layer of tissue that covers the front of the eye and lines the inside of the eyelids). It can be triggered by various allergens, such as pollen, pet dander, dust mites, or mold spores. The Allergic Conjunctivitis Market includes medications, eye drops, and therapies aimed at relieving the symptoms of allergic conjunctivitis, such as itching, redness, tearing, and swelling of the eyes.

Some of the commonly used treatment options include antihistamine eye drops, mast cell stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroid eye drops. Increased prevalence, rising awareness, and advancements in treatment options for allergic conjunctivitis are projected to create lucrative opportunities for the allergic conjunctivitis market. For instance, according to the Centers for Disease Control and Prevention, allergic conjunctivitis affects an estimated 20% of the general population in the United States. However, restraints like Limited therapeutic innovations and potential competition from alternative treatments hinder the allergic conjunctivitis market. Moreover, the introduction of newer drug products by many market players may aim to influence significant research and development in the allergic Conjunctivitis market. For instance, Eyevance Pharmaceutical launched Zerviate (cetirizine ophthalmic solution 0.24%) for the treatment of ocular itching associated with allergic conjunctivitis. Service is supplied as a solution for topical administration.

Recent Market Developments:

• In February 2021, Bausch & Lomb announced the launch of Alaway preservative-free (ketotifen fumarate 0.035 %) antihistamine eye drops as the first OTC preservative-free formulation eye drop.
• In February 2021, Alcon announced the broad retail availability of Pataday once daily relief extra strength in the US.
• In January 2023, ALK received an FDA grant for its Odactra Tablets for an expanded indication of allergic rhinitis in children ages 12 to 17.